One of the most striking: The company has shown that patients with certain types of hepatitis C respond as well to 24 weeks of Pegasys as they do to 48 weeks of PEG-intron.
The company is betting on studies showing that patients with certain strains of the hepatitis C virus can do with half as much time on Pegasys as they can on Schering-Plough 's (nyse: SGP - news - people ) Peg-Intron.
The company has tried to create new enthusiasm withwith efforts to expand into hepatitis C, the viral liver disease that is looking like the next big drug market, and into other areas such as heart disease, cystic fibrosis, and pulmonary arterial hypertension.